The effects of lycopene supplementation on serum insulin-like growth factor 1 (IGF-1) levels and cardiovascular disease: A dose-response meta-analysis of clinical trials

Xie, Zhihong; Yang, Feng

doi:10.1016/j.ctim.2020.102632

Cited by 7 publications

(6 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall conclusion presented herein is in accordance with the previous reviews that did not support the efficacy of lycopene in improving serum IGF‐1 levels (Janjuha et al, 2020; Xie & Yang, 2020); however, there are some concerns limiting the validity of their results. The meta‐analysis by Xie et al, missed three eligible well‐designed RCTs (Gann et al, 2015; Talvas et al, 2010; Voskuil et al, 2008) which caused a loss of 258 participants.…”

Section: Discussionsupporting

confidence: 91%

“…The overall conclusion presented herein is in accordance with the previous reviews that did not support the efficacy of lycopene in improving serum IGF-1 levels (Janjuha et al, 2020;Xie & Yang, 2020); however, there are some concerns limiting the validity of their results.…”

Section: Discussionsupporting

confidence: 90%

“…In addition, this review missed three eligible studies in the analysis (Biernacka et al, 2019; Schwarz et al, 2008; Talvas et al, 2010). Similarly, another meta‐analysis demonstrated no significant associations between lycopene supplementation and IGF‐1 levels (Xie & Yang, 2020); however, some limitations render the results unreliable, including missing three eligible, well‐designed, RCTs (258 participants) (Gann et al, 2015; Talvas et al, 2010; Voskuil et al, 2008), and insufficient explanation on how to calculate the effect size for two articles that did not report enough data for pairwise comparisons (Biernacka et al, 2019; Walfisch et al, 2007). Therefore, in an effort to discern more reliable results, we performed a systematic review of RCTs that investigated the impact of lycopene supplementation on circulating IGF‐1 and IGFBPs concentrations in adults.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The effects of lycopene supplementation on insulin‐like growth factor‐1 and insulin‐like growth factor binding proteins: A systematic review of randomized controlled trials

Meshkini

Ramezani‐Jolfaie

Sargazi

et al. 2022

Phytotherapy Research

View full text Add to dashboard Cite

Lycopene has been posited to regulate insulin-like growth factor-1 (IGF-1). We aimed to conduct a systematic review of the effects of lycopene on circulating IGF-1 and insulin-like growth factor binding proteins (IGFBPs) in adults. A systematic search was carried out in PubMed, Scopus, ISI Web of Science, and the Cochrane Library databases for randomized controlled trials (RCTs), published from inception until March 2020. A total of 11 studies fulfilled the selection criteria. Eleven studies examined the effect of lycopene supplementation on IGF-1, one of which reported a significant reduction. Moreover, three, four, and ten studies were found for IGFBP-1, IGFBP-2, and IGFBP-3, respectively; where one study found a significant increase in these proteins. In conclusion, no consistent modifying effect of lycopene supplementation on IGF-1 and IGFBPs levels are evident in the literature. More research is needed to explore the effect of lycopene on IGF-1 system.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effects of lycopene supplementation on insulin‐like growth factor‐1 and insulin‐like growth factor binding proteins: A systematic review of randomized controlled trials

Meshkini

Ramezani‐Jolfaie

Sargazi

et al. 2022

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…Research proves a correlation between the incidence of myocardial infarction with serum lycopene levels in 11 countries by EURAMIC (Joshi et al, 2020). Another risk factor for ischemic heart disease is the level of IGF-1 which appears to be modulated in action by lycopene from tomatoes and other properties of inhibiting platelet aggregation (Xie & Yang, 2020). Other ingredients such as retinol in tomatoes, which are fat-soluble, make LDL more resistant to oxidation (McKay et al, 2020).…”

Section: Results and Discussion Ischaemic Hearth Disease And Strokementioning

confidence: 99%

Tomato Role on Seven Deadliest Non-Communicable Disease

Zulfa¹,

Salim

Silalahi

et al. 2021

jiss

View full text Add to dashboard Cite

Non-communicable diseases such as ischemic heart disease, stroke, chronic obstructive pulmonary disease, lung cancer, Alzheimer, diabetes melitus, and kidney disease are leading causes of death in the world. There are many risk factors which can contribute to non-communicable diseases such as dietary. Vegetable consumption such as tomato may lower risk factors to non-communicable diseases because of its active ingredient, lycopene, retinol, alpha tomatine, and tomatidine. In this study, authors aim to explain the mechanism of tomato’s active compound in lowering risk factors of non-communicable disease based on biomarker found on each disease collected from recent epidemiological, in silico, in vitro, and in vivo researches. Lycopene and retinol have proven in reducing ischemic heart disease and stroke because of its anti-atherogenic properties and anti-inflammatory effect. Anti-oxidative and anti-inflammatory effect of lycopene also proven in lowering risk factors of chronic obstructive pulmonary diseases by modulate reverse cholesterol transport, so cholesterol homeostasis is created. In lung cancer, lycopene and other bioactive compound such as α-tomatine and tomatidine also have an anti-proliferative effect by interacting with Epidermal growth factor receptor (EGFR). Its ability to reduce the final product of lipid peroxidation level makes lycopene lower Alzheimer risk factor. There is much more function of tomato’s active coumpound although pure tomato has contradictive effect on some disease.

show abstract

“…The exact mechanisms through which lycopene and FruHis affect serum IGF-1 and TPSA levels are unknown. Although the physiological effects of FruHis have not been studied yet, there are some studies on lycopene ( 38 , 39 ). It is proposed that lycopene contributes to some physiological pathways through inhibition of cell cycle progression, interleukin-6 expression, and androgen activation and signaling ( 38 , 39 ).…”

Section: Discussionmentioning

confidence: 99%

FruHis significantly increases the anti-benign prostatic hyperplasia effect of lycopene: A double-blinded randomized controlled clinical trial

Sadeghi

Saedisomeolia²,

Jalili‐Baleh³

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

BackgroundFor decades, lycopene was considered the main compound of tomato protecting benign prostatic hyperplasia (BPH). Recent animal studies suggest that a newly discovered compound “FruHis” boosts lycopene for its action. This study aimed to determine whether FruHis enhances the action of lycopene to modify the laboratory parameters and clinical outcomes of patients with BPH.Materials and methodsCurrent study was conducted on 52 BPH patients, who were randomly assigned into four groups of treatments: lycopene plus FruHis (n = 11, 25 mg/day lycopene and 10 mg/day FruHis), lycopene (n = 12, 25 mg/day lycopene), FruHis (n = 12, 10 mg/day FruHis), and placebo (n = 13). Patients received these supplements for 8 weeks.ResultsFruHis intake strengthened the reducing effects of lycopene on insulin-like growth factor-1 (IGF-1) (−54.47 ± 28.36 ng/mL in the lycopene + FruHis group vs. −30.24 ± 46.69 ng/mL in the lycopene group), total prostate-specific antigen (TPSA) (−1.49 ± 4.78 ng/mL in the lycopene + FruHis group vs. −0.64 ± 2.02 ng/mL in the lycopene group), and symptom score (−4.45 ± 4.03 in the lycopene + FruHis group vs. −1.66 ± 5.41 in the lycopene group) in BPH patients. Such findings were also seen for body mass index (BMI) and waist circumference (WC). However, except for IGF-1, these reductions were not statistically significant compared with the placebo, and the intakes of lycopene and FruHis alone, however, were clinically important. Such effects of lycopene and FruHis were not seen for free PSA (FPSA) and FPSA/TPSA ratio.ConclusionDespite the non-significant effects of lycopene and FruHis, it seems that FruHis intake strengthens the beneficial effects of lycopene on IGF-1, TPSA, and symptom scores among BPH patients.Clinical trial registration[www.irct.ir], identifier [IRCT20190522043669N1].

show abstract

The effects of lycopene supplementation on serum insulin-like growth factor 1 (IGF-1) levels and cardiovascular disease: A dose-response meta-analysis of clinical trials

Cited by 7 publications

References 65 publications

The effects of lycopene supplementation on insulin‐like growth factor‐1 and insulin‐like growth factor binding proteins: A systematic review of randomized controlled trials

The effects of lycopene supplementation on insulin‐like growth factor‐1 and insulin‐like growth factor binding proteins: A systematic review of randomized controlled trials

Tomato Role on Seven Deadliest Non-Communicable Disease

FruHis significantly increases the anti-benign prostatic hyperplasia effect of lycopene: A double-blinded randomized controlled clinical trial

Contact Info

Product

Resources

About